dc.contributor
Institut Català de la Salut
dc.contributor
[de la Cruz-Merino L] Medical Oncology Department, Virgen Macarena University Hospital, Medicine Department University of Seville, Seville, Spain. GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. [Gion M] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Cruz-Jurado J] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Quiroga V] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain. [Andrés R] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Moreno F] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain. [Cortés J] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. International Breast Cancer Center (IBCC), Quirón Teknon Hospital (Quironsalud Group), Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
de la Cruz-Merino, Luis
dc.contributor.author
Gion, María
dc.contributor.author
Cruz Jurado, Josefina
dc.contributor.author
Quiroga, Vanesa
dc.contributor.author
Andrés, Raquel
dc.contributor.author
Moreno, Fernando
dc.contributor.author
Cortés Castan, Javier
dc.date.accessioned
2025-10-25T05:36:45Z
dc.date.available
2025-10-25T05:36:45Z
dc.date.issued
2022-06-03T06:54:25Z
dc.date.issued
2022-06-03T06:54:25Z
dc.date.issued
2021-10-29
dc.identifier
Cruz-Merino L de la, Gion M, Cruz-Jurado J, Quiroga V, Andrés R, Moreno F, et al. Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers. 2021 Oct 29;13(21):5432.
dc.identifier
https://hdl.handle.net/11351/7621
dc.identifier
10.3390/cancers13215432
dc.identifier
000719460800001
dc.identifier.uri
http://hdl.handle.net/11351/7621
dc.description.abstract
Bomarkers; Breast cancer; Pembrolizumab
dc.description.abstract
Biomarcadores; Cáncer de mama; Pembrolizumab
dc.description.abstract
Biomarcadors; Càncer de mama; Pembrolizumab
dc.description.abstract
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab (day 1) plus gemcitabine (days 1 and 8). The primary objective was the objective response rate (ORR). The tumor infiltrating lymphocytes (TILs) density and PD-L1 expression in tumor, and the myeloid-derived suppressor cells (MDSCs) level in peripheral blood, were analyzed to explore associations with treatment efficacy. Considering a two-stage Simon’s design, the study recruitment was stopped after its first stage as statistical assumptions were not met. A subset of 21 triple-negative breast cancer (TNBC) patients was enrolled. Their median age was 49 years; 15 patients had visceral involvement, and 16 had ≤3 metastatic locations. Treatment discontinuation due to progressive disease (PD) was reported in 16 patients. ORR was 15% (95% CI 3.2–37.9). Four patients were on treatment >6 months before PD. Grade ≥3 treatment-related adverse events were observed in 8 patients, where neutropenia was the most common. No association was found between TILs density, PD-L1 expression or MDSCs levels and treatment efficacy. ORR in TNBC patients also did not meet the assumptions, but 20% were on treatment >6 months.
dc.description.abstract
The study was partially supported by a research grant from Merck’s (MSD in Europe) Investigator Initiated Studies Program, which also supplied the pembrolizumab.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Cancers;13(21)
dc.relation
https://doi.org/10.3390/cancers13215432
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Immunoteràpia
dc.subject
Mama - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.title
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
